title: An analysis of the variation of plasma concentrations of placental protein 14 in artificial cycles.
abstract: OBJECTIVE
  To analyze the factors affecting the variation of plasma concentration of placental protein 14 (PP14) in artificial cycles.
  
  
  METHODS
  The effects of different hormone replacement therapy (HRT) regimens were examined in a crossover design.
  
  
  METHODS
  Jessop Hospital for Women, Sheffield, United Kingdom.
  
  
  METHODS
  Eighteen women with premature ovarian failure: 6 associated with Turner's syndrome and 12 with idiopathic premature ovarian failure.
  
  
  METHODS
  Four different HRT regimens; 36 study cycles.
  
  
  METHODS
  Plasma PP14 concentrations on days 1, 15, 19, and 29 of the artificial cycles.
  
  
  RESULTS
  In cycles treated with a standard HRT, the levels were similar to those of the natural cycle. Subjects with Turner's syndrome did not have elevated PP14 levels, whereas the majority (9/12 [75%]) of those with idiopathic premature ovarian failure had elevated levels on day 29 of the cycle. Levels of PP14 were reduced when either the doses of estradiol valerate were reduced to 1/3 or the doses of progesterone (P) were reduced to 1/5 of the standard HRT.
  
  
  CONCLUSIONS
  Plasma levels of PP14 are dependent not only on P stimulation but also on adequate estrogen priming.
authors.affiliation: University of Sheffield, Sheffield City Polytechnic, United Kingdom.
authors.forename: T C
authors.initials: TC
authors.lastname: Li
authors.forename: C
authors.initials: C
authors.lastname: Dalton
authors.forename: A E
authors.initials: AE
authors.lastname: Bolton
authors.forename: E
authors.initials: E
authors.lastname: Ling
authors.forename: A
authors.initials: A
authors.lastname: Warren
authors.forename: I D
authors.initials: ID
authors.lastname: Cooke
mesh_terms: D000328:Adult; D004958:Estradiol / Q000097:blood / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D000071816:Glycodelin; D006023:Glycoproteins; D006801:Humans; D008597:Menstrual Cycle / Q000097:blood* / Q000187:drug effects; D011257:Pregnancy Proteins / Q000097:blood*; D016649:Primary Ovarian Insufficiency / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D011374:Progesterone / Q000097:blood; D012016:Reference Values; D014424:Turner Syndrome / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000071816:Glycodelin; D006023:Glycoproteins; C045246:PAEP protein, human; D011257:Pregnancy Proteins; D011374:Progesterone; D004958:Estradiol; D005640:Follicle Stimulating Hormone